Entereg Approval History 
- FDA approved: Yes (First approved May 20th, 2008)
- Brand name: Entereg
- Generic name: alvimopan
- Company: Adolor Corporation
- Treatment for: Postoperative Ileus
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection
surgery.
FDA Approval History for Entereg
| Date | Article |
|---|
| May 21, 2008 |  Adolor and GlaxoSmithKline Announce FDA Approval of Entereg
(alvimopan) for the Management of Postoperative Ileus (POI) |
| May 9, 2008 | Adolor Provides Regulatory Update on Entereg (alvimopan) |
| Feb 11, 2008 | FDA Extends Review of NDA for Entereg (alvimopan) |
| Jan 24, 2008 | Adolor and GlaxoSmithKline Report Favorable FDA Advisory Committee
Meeting for Entereg (alvimopan) for the Management of Postoperative
Ileus in Bowel Resection |
| Jan 18, 2008 | Adolor Announces Availability of Briefing Documents For January
23rd FDA Advisory Committee Meeting on Entereg (alvimopan) |
| Nov 28, 2007 | Adolor and GlaxoSmithKline Announce FDA Advisory Committee to
Review Entereg (alvimopan) for the Management of Postoperative
Ileus (POI) |
| Aug 28, 2007 | FDA Accepts for Review Complete Response to Approvable Letter for
Entereg (alvimopan) for POI |
| Jun 11, 2007 | GSK and Adolor Update Alvimopan (Entereg/Entrareg) Development
Program |
| Nov 6, 2006 | FDA Issues Approvable Letter for Entereg (alvimopan) for POI |
| May 31, 2006 | Adolor’s Complete Response to Approvable Letter Accepted for Review by FDA |
| Jul 22, 2005 | Adolor Receives FDA Approvable Letter for Entereg |
| Jan 10, 2005 | Adolor Announces FDA Update |
| Sep 8, 2004 | FDA Accepts Entereg for Review |
| Jun 28, 2004 | Adolor Completes Submission of NDA for Entereg |
| Jun 1, 2004 | Adolor Submits Second Portion of NDA for Entereg |
| May 7, 2004 | Adolor Submits First Portion of NDA for Entereg |
See also...
Entereg (alvimopan) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
